These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

480 related items for PubMed ID: 9684794

  • 1. Monitoring heparin therapy using activated partial thromboplastin time--results of a multicenter trial establishing the therapeutic range for SILIMAT, a reagent with high sensitivity to heparin.
    Toulon P, Boutière B, Horellou MH, Trzeciak MC, Samama MM.
    Thromb Haemost; 1998 Jul; 80(1):104-8. PubMed ID: 9684794
    [Abstract] [Full Text] [Related]

  • 2. The therapeutic range for heparin therapy: relationship between six activated partial thromboplastin time reagents and two heparin assays.
    Kitchen S, Preston FE.
    Thromb Haemost; 1996 May; 75(5):734-9. PubMed ID: 8725715
    [Abstract] [Full Text] [Related]

  • 3. Monitoring heparin therapy: relationships between the activated partial thromboplastin time and heparin assays based on ex-vivo heparin samples.
    van den Besselaar AM, Meeuwisse-Braun J, Bertina RM.
    Thromb Haemost; 1990 Feb 19; 63(1):16-23. PubMed ID: 2339357
    [Abstract] [Full Text] [Related]

  • 4. A comparison of the sensitivity of APTT reagents to the effects of enoxaparin, a low-molecular weight heparin.
    Ip BK, Thomson AR, Moriarty HT.
    Pathology; 2001 Aug 19; 33(3):347-52. PubMed ID: 11523938
    [Abstract] [Full Text] [Related]

  • 5. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R, Jacobs C.
    Res Vet Sci; 2001 Apr 19; 70(2):101-8. PubMed ID: 11356088
    [Abstract] [Full Text] [Related]

  • 6. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion.
    Guervil DJ, Rosenberg AF, Winterstein AG, Harris NS, Johns TE, Zumberg MS.
    Ann Pharmacother; 2011 Jul 19; 45(7-8):861-8. PubMed ID: 21712506
    [Abstract] [Full Text] [Related]

  • 7. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin.
    Levine MN, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, Anderson D, Johnson M.
    Arch Intern Med; 1994 Jan 10; 154(1):49-56. PubMed ID: 8267489
    [Abstract] [Full Text] [Related]

  • 8. Interlaboratory agreement in the monitoring of unfractionated heparin using the anti-factor Xa-correlated activated partial thromboplastin time.
    Cuker A, Ptashkin B, Konkle BA, Pipe SW, Whinna HC, Zheng XL, Cines DB, Pollak ES.
    J Thromb Haemost; 2009 Jan 10; 7(1):80-6. PubMed ID: 19017257
    [Abstract] [Full Text] [Related]

  • 9. The PiCT® test is a reliable alternative to the activated partial thromboplastin time in unfractionated heparin therapy management: results from a multicenter study.
    Brisset AC, Ferrández A, Krause M, Rathbun S, Marlar R, Korte W.
    J Thromb Haemost; 2016 Nov 10; 14(11):2187-2193. PubMed ID: 27582411
    [Abstract] [Full Text] [Related]

  • 10. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS, Menon V, Schappert J, Wilentz JR, Singh V, Hochman JS.
    J Thromb Thrombolysis; 2004 Apr 10; 17(2):121-6. PubMed ID: 15306747
    [Abstract] [Full Text] [Related]

  • 11. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin.
    Vandiver JW, Vondracek TG.
    Pharmacotherapy; 2012 Jun 10; 32(6):546-58. PubMed ID: 22531940
    [Abstract] [Full Text] [Related]

  • 12. Monitoring unfractionated heparin therapy: relationship between eight anti-Xa assays and a protamine titration assay.
    Kitchen S, Theaker J, Preston FE.
    Blood Coagul Fibrinolysis; 2000 Mar 10; 11(2):137-44. PubMed ID: 10759006
    [Abstract] [Full Text] [Related]

  • 13. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW, Vondracek TG.
    Hosp Pract (1995); 2013 Apr 10; 41(2):16-24. PubMed ID: 23545756
    [Abstract] [Full Text] [Related]

  • 14. Standardization of coagulation tests.
    Opartkiattikul N.
    Southeast Asian J Trop Med Public Health; 1999 Apr 10; 30 Suppl 3():79-85. PubMed ID: 10926265
    [Abstract] [Full Text] [Related]

  • 15. Clinical use of unfractionated heparin therapy in children: time for change?
    Newall F, Ignjatovic V, Johnston L, Summerhayes R, Lane G, Cranswick N, Monagle P.
    Br J Haematol; 2010 Sep 10; 150(6):674-8. PubMed ID: 20629660
    [Abstract] [Full Text] [Related]

  • 16. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin.
    Price EA, Jin J, Nguyen HM, Krishnan G, Bowen R, Zehnder JL.
    Ann Pharmacother; 2013 Feb 10; 47(2):151-8. PubMed ID: 23386070
    [Abstract] [Full Text] [Related]

  • 17. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time.
    Nath FC, Muller DW, Rosenschein U, Ellis SG, Topol EJ.
    Can J Cardiol; 1993 Nov 10; 9(9):797-801. PubMed ID: 8281479
    [Abstract] [Full Text] [Related]

  • 18. APTT therapeutic range for monitoring unfractionated heparin therapy. Significant impact of the anti-Xa reagent used for correlation.
    Toulon P, Smahi M, De Pooter N.
    J Thromb Haemost; 2021 Aug 10; 19(8):2002-2006. PubMed ID: 33555096
    [Abstract] [Full Text] [Related]

  • 19. Usefulness of cumulative summation of differences method for determining APTT reagent suitability.
    Findlater SH.
    Clin Lab Sci; 2012 Aug 10; 25(3):142-8. PubMed ID: 22953513
    [Abstract] [Full Text] [Related]

  • 20. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
    Takemoto CM, Streiff MB, Shermock KM, Kraus PS, Chen J, Jani J, Kickler T.
    Am J Clin Pathol; 2013 Apr 10; 139(4):450-6. PubMed ID: 23525615
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.